Drug Profile
Somavaratan - Aravive
Alternative Names: hGH-rPEG - Aravive; hGH-XTEN; Human growth hormone-XTEN - Amunix; Recombinant human growth hormone long-acting - Aravive; Somatropin derivative - Aravive; Somatropin long-acting - Aravive; Somatropin-fusion-protein-Aravive; VRS-317Latest Information Update: 25 Apr 2022
Price :
$50
*
At a glance
- Originator Versartis
- Developer Aravive; Teijin Pharma
- Class Growth hormones; Hormonal replacements; Recombinant fusion proteins
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 21 Apr 2022 Discontinued - Phase-II for Somatotropin deficiency (Treatment-experienced, In adults) in USA, Germany, Australia, United Kingdom (SC) as trial did not meet efficacy endpoint
- 21 Apr 2022 Discontinued - Phase-III for Somatotropin deficiency (In children, Treatment-naive) in Netherlands, Japan, Poland, Poland, Sweden, Canada, Belgium, USA (SC) as trial did not meet efficacy endpoint
- 17 Jan 2022 Amunix has been acquired by Sanofi